lifestyle.cfxmagazine.com

Author: Atsena Therapeutics

Atsena Presents Positive Interim Six-Month Results from Part B of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis

May 4, 2026
Atsena Therapeutics Announces Upcoming Presentations at Scientific and Medical Meetings

April 23, 2026
Atsena Therapeutics Receives Data Monitoring Committee Recommendation to Proceed with Pivotal Part C Cohort of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis

April 20, 2026